menu

Transformation of Treatment Strategies for ATTR Amyloidosis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Transformation of Treatment Strategies for ATTR Amyloidosis 

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.

Facebook Comments

Recommended
Details
Comments
  • Overview

    The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.

Facebook Comments

Schedule14 Jul 2024